论文信息 - Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial - 字舞流文

Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial

A. Keech | R. Giugliano | M. Sabatine | P. Sever | F. Mach | Z. Gaciong | J. López-Miranda | F. Schiele | B. Ott | R. Češka | I. Gouni-Berthold | T. Pedersen | S. Wasserman | K. Toth | Jeong-Gun Park | G. Ferrari | Estella Kanevsky | A. Pineda | R. Somaratne | Armando Lira Pineda | K. Tóth